← Back to Search

Cholinesterase Inhibitor

Pyridostigmine for Parkinson's Disease

Phase 2
Recruiting
Led By Lisa M Deuel, MD
Research Sponsored by University of Vermont Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 13-15 weeks
Awards & highlights
No Placebo-Only Group

Summary

This trial studies if pyridostigmine can help with constipation in people with Parkinson's Disease, as constipation can severely impact quality of life.

Who is the study for?
Adults with Parkinson's Disease who suffer from chronic constipation can join this trial. They must be able to take oral meds, follow the study plan, and use effective birth control if of childbearing potential. Excluded are those with bowel surgery history, severe lung conditions, atypical parkinsonism forms, pyridostigmine allergy or recent use.
What is being tested?
The trial is testing Pyridostigmine Bromide's effectiveness and safety in treating constipation for Parkinson’s patients. It aims to find a dedicated treatment where none currently exists specifically for these individuals.
What are the potential side effects?
While not explicitly listed here, common side effects of Pyridostigmine may include muscle cramps or twitching, changes in heart rate, pressure or pain in the stomach area, nausea or vomiting among others.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~13-15 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 13-15 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Defecation
Secondary study objectives
Changes from Baseline to the End of Study Visit in Beck Depression Inventory-II (BDI-II)
Constipation
Parkinson Disease
+4 more

Side effects data

From 2016 Phase 4 trial • 87 Patients • NCT02308124
3%
Headache
3%
dizziness
100%
80%
60%
40%
20%
0%
Study treatment Arm
Midodrine Only
Midodrine + Pyridostigmine
Pyridostigmine Only

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Pyridostigmine BromideExperimental Treatment1 Intervention
Open Label
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pyridostigmine Bromide
2002
Completed Phase 4
~590

Find a Location

Who is running the clinical trial?

University of Vermont Medical CenterLead Sponsor
42 Previous Clinical Trials
25,778 Total Patients Enrolled
Lisa M Deuel, MDPrincipal InvestigatorUniversity of Vermont

Media Library

Pyridostigmine Bromide (Cholinesterase Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05603715 — Phase 2
Parkinson's Disease Research Study Groups: Pyridostigmine Bromide
Parkinson's Disease Clinical Trial 2023: Pyridostigmine Bromide Highlights & Side Effects. Trial Name: NCT05603715 — Phase 2
Pyridostigmine Bromide (Cholinesterase Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05603715 — Phase 2
~5 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top